Download pdf
The anticoagulant ability of lumbrokinase and the advantages of different dosage forms
- 1 Nanjing University of Chinese Medicine
* Author to whom correspondence should be addressed.
Abstract
As a traditional Chinese medicine, earthworms were found to have an effective thrombolytic effect in which lumbrokinase, an active ingredient, is now usually purified for the treatment of cardiovascular diseases. As a highly safe and easy-to-obtain drug, lumbrokinase is often administered in the form of enteric-coated tablets. However, there is still a lack of relevant research on the detailed molecular mechanism of lumbrokinase’s anticoagulant mechanism, the effectiveness and safety of long-term use, the interaction with other drugs, and the expansion and optimization of clinical applications. This paper analyzes the mechanism of action of lumbrokinase, the influencing factors of external conditions, the method of administration and the research of new drug delivery systems. It provides a reference for future research on the role and application prospects of lumbrokinase in anticoagulation. However, the specific molecular mechanism of action and clinical application issues have not been resolved. Future research can focus on the molecular mechanism of action and the efficiency and safety of clinical use of new drug systems.
Keywords
Lumbrokinase, anticoagulation, thrombus, novel drug delivery system.
[1]. Amini M Zayeri F & Saleh M 2017 Trend analysis of cardiovascular disease mortality incidence and mortality-to-incidence ratio: Results from global burden of disease study
[2]. Asada Y Yamashita A Sato Y & Hatakeyama K 2018 Thrombus formation and propagation in the onset of cardiovascular events J Atheroscler Thromb 25 8 653-664
[3]. Mancia G Fagard R Narkiewicz K et al 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension ESH and of the European Society of Cardiology ESC
[4]. Piepoli M F Hoes A W Agewall S et al 2016 European guidelines on cardiovascular disease prevention in clinical practice
[5]. Capodanno D Mehran R Valgimigli M et al 2018 Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
[6]. Wang X Hao L & Li H 2001 Observations on the efficacy of earthworm fibrinolytic enzyme and aspirin in treating hyperfibrinogenemia Chin J Integr Tradit West Med 17 72 95
[7]. Wang C Zhang H & Wang Y 2010 Advances in the study of earthworm fibrinolytic enzyme Med J Shenyang Mil Reg 23 3 201
[8]. Fan Q Wu C Li L Fan R Wu C Hou Q & He R 2001 Some features of intestinal absorption of intact fibrinolytic enzyme III-1 from Lumbricus rubellus Biochim Biophys Acta 1526 3 286-292
[9]. Wang X Zhang Y Pan R & He R 2010 Characteristics of transport and distribution of orally administered earthworm fibrinolytic enzyme in the gastrointestinal tract of rats Chin J New Drugs 15 1360-1364
[10]. You X Zhu K Liu J et al 2023 Research progress on drug delivery systems based on platelets and their derivatives Chin J Blood Transfus 36 11 1068-1073
[11]. Gay L J & Fielding-Habermann B 2011 Contribution of platelets to tumor metastasis Nat Rev Cancer 11 2 123-134
[12]. Wang S Wang R Meng N et al 2020 Platelet membrane-functionalized nanoparticles with improved targeting ability and lower hemorrhagic risk for thrombolysis therapy J Control Release 328 78-86
[13]. Kolas M Kumar P Choonara Y E et al 2019 Hypothesis: Can drug-loaded platelets be used as delivery vehicles for blood-brain barrier penetration? Med Hypotheses 125 75-78
[14]. Chen Y X Wei C X Lyu Y Q et al 2020 Biomimetic drug-delivery systems for the management of brain diseases Biomater Sci 8 4 1073-1088
[15]. Zhu C Ma J Ji Z et al 2021 Recent advances of cell membrane coated nanoparticles in treating cardiovascular disorders Molecules 26 11 3428
[16]. Li S Zhang K Ma Z et al 2022 Biomimetic nanoplatelets to target delivery hirudin for site-specific photothermal photodynamic thrombolysis and preventing venous thrombus formation Small 18 51 e2203184
Cite this article
Xie,Y. (2024). The anticoagulant ability of lumbrokinase and the advantages of different dosage forms. Theoretical and Natural Science,59,45-50.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).